simian immunodeficiency virus

Summary

Summary: Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV.

Top Publications

  1. ncbi Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells
    Jiangmei Yin
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    AIDS 22:1739-48. 2008
  2. ncbi Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection
    Rong Xu
    Seattle Biomedical Research Institute, Seattle, WA 98109, USA
    Virology 349:276-89. 2006
  3. ncbi The HIV-1 clade C promoter is particularly well adapted to replication in the gut in primary infection
    Mireille Centlivre
    Unite de Retrovirologie Moleculaire, Institut Pasteur, Paris, France
    AIDS 20:657-66. 2006
  4. ncbi Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques
    Rama Rao Amara
    Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA
    Virology 343:246-55. 2005
  5. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
  6. pmc V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques
    Siu hong Ho
    Rockefeller University, Aaron Diamond AIDS Research Center, 455 First Ave, 7th Floor, New York, NY 10016, USA
    J Virol 79:12296-303. 2005
  7. ncbi Increased viral replication in simian immunodeficiency virus/simian-HIV-infected macaques with self-administering model of chronic alcohol consumption
    Rakesh Kumar
    Laboratory of Viral Immunology, Department of Microbiology, Ponce School of Medicine, San Juan, PR
    J Acquir Immune Defic Syndr 39:386-90. 2005
  8. pmc Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus
    Christopher J Miller
    Center for Comparative Medicine, University of California Davis, Davis, CA 95616, USA
    J Virol 79:9217-27. 2005
  9. ncbi Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 174:4753-60. 2005
  10. pmc Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells
    Gerald V Quinnan
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    J Virol 79:3358-69. 2005

Detail Information

Publications62

  1. ncbi Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells
    Jiangmei Yin
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    AIDS 22:1739-48. 2008
    ..In this follow-up study, we measured viral replication 2 years after vaccination challenge and determined the mechanism by which antigen-specific CD8 T cells suppress viral replication...
  2. ncbi Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection
    Rong Xu
    Seattle Biomedical Research Institute, Seattle, WA 98109, USA
    Virology 349:276-89. 2006
    ..Our results suggest that even small differences in HIV Envelope immunogen structure can affect the neutralizing antibody responses generated following infection...
  3. ncbi The HIV-1 clade C promoter is particularly well adapted to replication in the gut in primary infection
    Mireille Centlivre
    Unite de Retrovirologie Moleculaire, Institut Pasteur, Paris, France
    AIDS 20:657-66. 2006
    Coinfection of rhesus macaques with human/simian immunodeficiency virus chimeras harbouring the minimal core-promoter/enhancer elements from HIV-1 clade B, C and E viral prototypes (STR-B, STR-C and STR-E) revealed a remarkable dichotomy ..
  4. ncbi Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques
    Rama Rao Amara
    Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA
    Virology 343:246-55. 2005
    ..6P control. They also suggest a dynamic relationship between neutralizing Ab, antigen load and anti-viral CD4 cells in the maturation of high-quality anti-viral CD8 T cells...
  5. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
    ..expressing human immunodeficiency virus type 1 (HIV-1) Tat (Ad5/HIVTat); (ii) Ad5 vector expressing simian immunodeficiency virus (SIV) Gag (Ad5/SIVGag); (iii) Ad5 vector expressing the truncated HIV-1(jrfl) Env, gp140 (Ad5/..
  6. pmc V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques
    Siu hong Ho
    Rockefeller University, Aaron Diamond AIDS Research Center, 455 First Ave, 7th Floor, New York, NY 10016, USA
    J Virol 79:12296-303. 2005
    ..These findings in a unique isogenic system illustrate that coreceptor usage is the principal determinant of tissue and target cell specificity of the virus in vivo and dictates the dynamics of CD4+-T-cell depletion during SHIV infection...
  7. ncbi Increased viral replication in simian immunodeficiency virus/simian-HIV-infected macaques with self-administering model of chronic alcohol consumption
    Rakesh Kumar
    Laboratory of Viral Immunology, Department of Microbiology, Ponce School of Medicine, San Juan, PR
    J Acquir Immune Defic Syndr 39:386-90. 2005
    ..was designed to determine the effect of alcohol dependence on virus replication and CD4 profiles in simian immunodeficiency virus/simian-HIV-infected rhesus macaques...
  8. pmc Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus
    Christopher J Miller
    Center for Comparative Medicine, University of California Davis, Davis, CA 95616, USA
    J Virol 79:9217-27. 2005
    ..using an animal model in which female rhesus macaques were exposed intravaginally to a high dose of simian immunodeficiency virus (SIV)...
  9. ncbi Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 174:4753-60. 2005
    ..Persisting clinical protection in vaccinated and challenged monkeys is thus correlated with a preserved capacity of the peripheral blood central memory CD4+ T cells to express this important immunomodulatory cytokine...
  10. pmc Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells
    Gerald V Quinnan
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    J Virol 79:3358-69. 2005
    ..Concurrently, groups of monkeys received expression vectors that encoded either simian immunodeficiency virus (SIV) gag/pol genes or no SIV genes in vivo to test the additional protective benefit of concurrent ..
  11. ncbi Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates
    Paul M Waterman
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland, USA
    Viral Immunol 17:545-57. 2004
    ..6) nef-deleted vaccination, likely reflects differences in replication capacity. The protective effect of nef-deleted virus was partly restored by expressing Type 1 chemokines to augment viral immunity...
  12. ncbi Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination
    Y Enose
    Institute for Virus Research, Kyoto University, Kyoto, Japan
    Arch Virol 149:1705-20. 2004
    ....
  13. pmc Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque
    Philip M McKenna
    Department of Microbiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    J Virol 78:13455-9. 2004
    ..6P). There was no evidence of CD4(+) T-cell loss, and plasma viremia was controlled to undetectable levels by 6 weeks postchallenge and has remained suppressed out to 22 weeks postchallenge...
  14. ncbi Stimulation of virus-specific T cell responses by dendritic cell vaccination in the chronic phase of simian AIDS models
    Moriaki Kato
    Department of Microbiology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 0033, Japan
    Jpn J Infect Dis 57:220-3. 2004
    ....
  15. ncbi Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques
    Nataliya Trunova
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Virology 352:169-77. 2006
    ....
  16. pmc Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys
    Norman L Letvin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 312:1530-3. 2006
    Vaccine-induced cellular immunity controls virus replication in simian immunodeficiency virus (SIV)-infected monkeys only transiently, leading to the question of whether such vaccines for AIDS will be effective...
  17. ncbi Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques
    Hiroyuki Yamamoto
    International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Tokyo 108 8639, Japan
    J Gen Virol 88:652-9. 2007
    ..T-cell depletion leading to an acute crash of the host immune system, whereas pathogenic R5-tropic simian immunodeficiency virus (SIV) infection, like HIV-1 infection in humans, results in chronic disease progression in macaques...
  18. pmc Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial
    Miki Kawada
    International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    J Virol 82:10199-206. 2008
    ..T lymphocytes (CTLs) exert strong suppressive pressure on human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication...
  19. pmc Impact of MHC class I diversity on immune control of immunodeficiency virus replication
    Philip J R Goulder
    Department of Paediatrics, Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
    Nat Rev Immunol 8:619-30. 2008
    ..Here, we review recent studies of T-cell-mediated control of HIV and SIV infection, and offer insight for the design of a successful T-cell-based HIV vaccine in the future...
  20. pmc Small intestine CD4+ T cells are profoundly depleted during acute simian-human immunodeficiency virus infection, regardless of viral pathogenicity
    Yoshinori Fukazawa
    Laboratory of Primate Model, Experimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, 53 Shogoinkawaramachi, Sakyo ku, Kyoto 606 8507, Japan
    J Virol 82:6039-44. 2008
    ..We conclude that SHIV, regardless of pathogenicity, can cause injury to the small intestine and leads to CD4(+) T-cell depletion in infected animals during acute infection...
  21. pmc Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys
    Ronald S Veazey
    Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana 70433, USA
    J Virol 82:5618-30. 2008
    Previously we have shown that CD8(+) T cells are critical for containment of simian immunodeficiency virus (SIV) viremia and that rapid and profound depletion of CD4(+) T cells occurs in the intestinal tract of acutely infected macaques...
  22. ncbi Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques
    L Jean Patterson
    Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Virology 374:322-37. 2008
    ..Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected...
  23. pmc IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses
    Yvonne M Mueller
    Department of Microbiology and Immunology, and Center for Immunology and Vaccine Science, Drexel University College of Medicine, Philadelphia, PA 19129, USA
    J Immunol 180:350-60. 2008
    ..Finally, IL-15-treated acutely SIV-infected primates may serve as a useful model to investigate the poorly understood mechanisms that control viral set point and disease progression in HIV infection...
  24. pmc Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail
    Pramod N Nehete
    Department of Veterinary Sciences, The University of Texas M D Anderson Cancer Center, Bastrop, TX 78602, USA
    Virology 370:130-41. 2008
    ..These results support DC-based vaccine delivery and the utility of the conserved HIV-1 envelope peptide-cocktail, capable of priming strong cell-mediated immunity, for potential inclusion in HIV vaccination strategies...
  25. pmc Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques
    Tetsuo Tsukamoto
    International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    J Virol 81:11640-9. 2007
    ..immunodeficiency virus (SHIV) replication but difficulty in containment of pathogenic CCR5-tropic simian immunodeficiency virus (SIV) in rhesus macaques...
  26. ncbi Simian immunodeficiency virus infection induces severe loss of intestinal central memory T cells which impairs CD4+ T-cell restoration during antiretroviral therapy
    D Verhoeven
    Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616, USA
    J Med Primatol 36:219-27. 2007
    b>Simian immunodeficiency virus (SIV) infection leads to severe loss of intestinal CD4(+) T cells and, as compared to peripheral blood, restoration of these cells is slow during antiretroviral therapy (ART)...
  27. ncbi Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors
    Misa Ishimatsu
    Laboratory for Viral Replication, Center for Emerging Virus Research, Institute for Virus Research, Kyoto University, 53 Shogoin Kawaracho, Kyoto 606 8507, Japan
    Microbes Infect 9:475-82. 2007
    ..The results suggest that SHIV-pr can be used to evaluate PR inhibitors using monkeys...
  28. pmc Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine
    Miki Kawada
    International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    J Virol 81:5202-11. 2007
    ..we present three rhesus macaques that successfully maintained Env-independent vaccine-based control of simian immunodeficiency virus (SIV) mac239 replication without disease progression for more than 3 years...
  29. ncbi Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques
    Anna Hryniewicz
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Building 41, Bethesda, MD 20892, USA
    J Immunol 178:3492-504. 2007
    ..These results underscore the importance of testing immunomodulatory approaches in vivo to assess potential risks and benefits for HIV-1-infected individuals...
  30. pmc Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans
    Lily Tsai
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Virology 362:207-16. 2007
    ..These data have implications for HIV-1 transmission and infection in humans...
  31. pmc Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus
    Rakesh Kumar
    Laboratory of Viral Immunology, Department of Microbiology, Ponce School of Medicine, Ponce 00732, Puerto Rico
    J Virol 78:11425-8. 2004
    ..6P), and simian immunodeficiency virus 17E-Fr...
  32. ncbi Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses
    Steven M Wolinsky
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Virology 328:19-29. 2004
    ..In neither animal was the increase in X4 viral load sustained throughout therapy, however. These observations may have relevance for the development of CCR5 inhibitors for treatment of HIV-1 infection of humans...
  33. ncbi Therapeutic dendritic-cell vaccine for simian AIDS
    Wei Lu
    Institut de Recherche sur les Vaccins et l Immunothérapie des cancers et du SIDA, Paris, France
    Nat Med 9:27-32. 2003
    An effective immune response against human immunodeficiency virus or simian immunodeficiency virus (SIV) is critical in achieving control of viral replication...
  34. ncbi Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy
    Elzbieta Tryniszewska
    Basic Research Laboratory, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 169:5347-57. 2002
    ..These data provide the proof of concept that therapeutic vaccination before cessation of ART may be a feasible approach in the clinical management of HIV-1 infection...
  35. ncbi Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses
    Zdenek Hel
    Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:4778-87. 2002
    ..The results presented in this work also further demonstrate the potential of a DNA-prime/attenuated poxvirus-boost vaccine regimen in an animal model that well mirrors human AIDS...
  36. ncbi Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection
    T B Kwofie
    Laboratory of Viral Pathogenesis, Research Center for AIDS, Institute for Virus Research, Kyoto University, Japan
    Arch Virol 147:1091-104. 2002
    ..This further enhances the prospects of this nef-deleted SHIV as the bases for effective anti-HIV vaccine candidates...
  37. pmc Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines
    Rama Rao Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    J Virol 76:7625-31. 2002
    ..Thus, MVA vaccines, as well as DNA/MVA vaccines, merit further evaluation for their ability to control the current AIDS pandemic...
  38. pmc Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression follow
    Helen Horton
    Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin 53715, USA
    J Virol 76:7187-202. 2002
    ..DNA prime/modified vaccinia virus Ankara boost regimen to immunize rhesus macaques against nearly all simian immunodeficiency virus (SIV) proteins...
  39. ncbi Understanding the basis of CD4(+) T-cell depletion in macaques infected by a simian-human immunodeficiency virus
    Bijan Etemad-Moghadam
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
    Vaccine 20:1934-7. 2002
    ....
  40. ncbi IL-4 increases Simian immunodeficiency virus replication despite enhanced SIV immune responses in infected rhesus macaques
    J D Boyer
    Department of Pathology, University of Pennsylvania, 422 Curie Blvd, 505 Stellar Chance Labs, Philadelphia, PA, USA
    Int J Parasitol 32:543-50. 2002
    ..Accordingly, the simian immunodeficiency virus (SIV) infected rhesus macaque model was used to investigate the impact of immunisation with SIV ..
  41. ncbi Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
    Dan H Barouch
    Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Research East Room 113, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 415:335-9. 2002
    ..described in humans infected with human immunodeficiency virus (HIV) and monkeys infected with simian immunodeficiency virus (SIV)...
  42. ncbi Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of simian immunodeficiency virus (SIV) in rhesus monkeys have shown that resolution of the acute viral infection and control of the subsequent ..
  43. pmc The simian immunodeficiency virus deltaNef vaccine, after application to the tonsils of Rhesus macaques, replicates primarily within CD4(+) T cells and elicits a local perforin-positive CD8(+) T-cell response
    Christiane Stahl-Hennig
    German Primate Center, 37077 Gottingen, Germany
    J Virol 76:688-96. 2002
    Deletion of the nef gene from simian immunodeficiency virus (SIV) strain SIVmac239 yields a virus that undergoes attenuated growth in rhesus macaques and offers substantial protection against a subsequent challenge with some SIV wild-..
  44. ncbi Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys
    Paul F McKay
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Immunol 168:332-7. 2002
    ..Moreover, an AIDS vaccine that confers protection against clinical disease evolution in this experimental model also preserves the functional capacity of these CTL to produce both IL-2 and TNF-alpha...
  45. ncbi An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
    N F Rose
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Cell 106:539-49. 2001
    ..Protection from AIDS was highly significant (p = 0.001). VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection...
  46. ncbi Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing interleukin-4 or interferon-gamma
    Christiane Stahl-Hennig
    Deutsches Primatenzentrum, Gottingen, Germany
    Virology 305:473-85. 2003
    ..However, SIV-IL4 and SIV-IFN induced protection against a homologous challenge virus. Subsequent challenge with an SIV-HIV-1 hybrid virus (SHIV) also revealed protection in the absence of neutralizing antibodies...
  47. pmc Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination
    Paul F McKay
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:4695-702. 2003
    ..of the capacity of peripheral blood CD4(+) T lymphocytes to express cytokines was first detected in simian immunodeficiency virus-infected monkeys during the peak of viral replication during primary infection and persisted ..
  48. ncbi A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A
    Nina Malkevitch
    Basic Research Laboratory, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 170:4281-9. 2003
    ..Our data confirm the potency and persistence of functional cellular immune responses elicited by replication competent Ad-recombinant priming. The cellular immunity elicited is broad and extends to subdominant epitopes...
  49. pmc Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection
    Miles P Davenport
    Department of Haematology, Prince of Wales Hospital, Kensington, New South Wales, Australia
    J Virol 78:10096-103. 2004
    ..However, this response is too little too late to prevent establishment of persistent infection...
  50. pmc Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein
    Silvija I Staprans
    Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30329, USA
    Proc Natl Acad Sci U S A 101:13026-31. 2004
    ..An attenuated recombinant varicella-zoster virus vaccine expressing the simian immunodeficiency virus (SIV) envelope (Env) elicited nonneutralizing Env-binding antibodies and little if any cytotoxic T ..
  51. ncbi Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys
    Maria Teresa Maggiorella
    Laboratory of Virology, Istituto Superiore di Sanita, Viale Regina Elena, 299, 00161 Rome, Italy
    Vaccine 22:3258-69. 2004
    ....
  52. ncbi Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques
    Daria J Hazuda
    Department of Biological Chemistry, Merck Research Laboratories, Post Office Box 4, West Point, PA 19486, USA
    Science 305:528-32. 2004
    ..These studies demonstrate integrase inhibitor activity in vivo and suggest that cellular immunity facilitates chemotherapeutic efficacy in retroviral infections...
  53. pmc High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum
    Lisa LaFranco-Scheuch
    Center for Comparative Medicine, California National Primate Research Center, University of California Davis, 1 Shields Ave, Davis, CA 95616, USA
    J Virol 78:6399-408. 2004
    ..antiviral CD8+ cytotoxic T lymphocytes, has been described for human immunodeficiency virus and simian immunodeficiency virus (SIV) infections...
  54. pmc Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication
    David A Garber
    Emory Vaccine Center, Atlanta, Georgia 30329, USA
    J Clin Invest 113:836-45. 2004
    In vivo blockade of CD28 and CD40 T cell costimulation pathways during acute simian immunodeficiency virus (SIV) infection of rhesus macaques was performed to assess the relative contributions of CD4+ T cells, CD8+ T cells, and Ab ..
  55. pmc Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol
    Elizabeth Ramsburg
    Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Virol 78:3930-40. 2004
    ..macaques with attenuated vesicular stomatitis virus (VSV) vectors encoding Env and Gag proteins of simian immunodeficiency virus-human immunodeficiency virus (SHIV) hybrid viruses protect rhesus macaques from AIDS after challenge ..
  56. pmc Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection
    Petra Mooij
    Department of Virology, Biomedical Primate Research Center, 2280 GH Rijswijk, The Netherlands
    J Virol 78:3333-42. 2004
    ..These data support the rationale that effective HIV vaccine-induced immunity requires a combination of potent Th1- and Th2-like responses best directed to multiple antigens...
  57. ncbi The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 320:75-84. 2004
    ....
  58. ncbi Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques
    Janos Nacsa
    Basic Research Laboratory, National Cancer Institute, 41 D804 Bethesda, MD 20892 5055, USA
    Vaccine 22:597-606. 2004
    The ability of ALVAC- or fowlpox-based simian immunodeficiency virus (SIV) vaccines to boost SIV-specific CD4+ and CD8+ T-cell responses was tested in 10 vaccinia-experienced macaques infected with SIVmac251...
  59. ncbi IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques
    Marie Thérèse Nugeyre
    Unité de Biologie des Rétrovirus Institut Pasteur, Paris, France
    J Immunol 171:4447-53. 2003
    ..No alarming modulation of the other hemopoietic cells was observed. No increase in the viral load was shown in blood or lymph nodes. These data strengthen the rationale for the use of IL-7 as an efficient immunotherapy in AIDS...
  60. ncbi Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type 1
    Hisashi Akiyama
    Institute for Virus Research, Laboratory of Viral Pathogenesis, Kyoto University, 53 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    J Gen Virol 84:1663-9. 2003
    ..SHIVrt/3rn, having part of HIV-1 pol in addition to the 3' part of the HIV-1 genome is genetically more close to HIV-1 than any of the other monkey-infecting SHIVs reported previously...
  61. ncbi Anti-HIV and -SIV immunity in the vagina
    Christopher J Miller
    Virology and Immunology Unit, California Regional Primate Research Center and Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California 95616, USA
    Int Rev Immunol 22:65-76. 2003
    ..HIV/SIV-specific CD8+ cytotoxic T lymphocytes are present in the cervicovaginal mucosa of infected women and rhesus macaques. A vaccine that can elicit strong antiviral immunity may provide protection for hetorosexual HIV-1 transmission...
  62. ncbi Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    R R Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329, USA
    Science 292:69-74. 2001
    ..These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic...